Ignite Creation Date:
2025-12-24 @ 3:14 PM
Ignite Modification Date:
2026-02-03 @ 7:03 PM
Study NCT ID:
NCT03163992
Status:
COMPLETED
Last Update Posted:
2022-08-08
First Post:
2017-04-26
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib
Sponsor:
Samsung Medical Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-12-26
Start Date Type:
ACTUAL
Primary Completion Date:
2021-05-17
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-05-17
Completion Date Type:
ACTUAL
First Submit Date:
2017-04-26
First Submit QC Date:
None
Study First Post Date:
2017-05-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2022-03-02
Results First Submit QC Date:
None
Results First Post Date:
2022-08-04
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-08-04
Last Update Post Date:
2022-08-08
Last Update Post Date Type:
ACTUAL